Willow Historical Income Statement
| WLLW Stock | CAD 0.08 0.01 5.88% |
Historical analysis of Willow Biosciences income statement accounts such as Interest Expense of 149.1 K, Selling And Marketing Expenses of 18.1 K, Other Operating Expenses of 15.4 M or Total Operating Expenses of 13.4 M can show how well Willow Biosciences performed in making a profits. Evaluating Willow Biosciences income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Willow Biosciences's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Willow Biosciences latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Willow Biosciences is a good buy for the upcoming year.
Willow |
About Willow Income Statement Analysis
Willow Biosciences Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Willow Biosciences shareholders. The income statement also shows Willow investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Willow Biosciences Income Statement Chart
Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Willow Biosciences. It is also known as Willow Biosciences overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Net Income
Net income is one of the most important fundamental items in finance. It plays a large role in Willow Biosciences financial statement analysis. It represents the amount of money remaining after all of Willow Biosciences operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Depreciation And Amortization
The systematic reduction in the recorded value of an intangible asset. This includes the allocation of the cost of tangible assets to periods in which the assets are used, representing the expense related to the wear and tear, deterioration, or obsolescence of physical assets and intangible assets over their useful lives.Most accounts from Willow Biosciences' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Willow Biosciences current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Willow Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. At this time, Willow Biosciences' Net Interest Income is very stable compared to the past year. As of the 4th of December 2024, Total Revenue is likely to grow to about 1.2 M, while Selling And Marketing Expenses is likely to drop about 18.1 K.
Willow Biosciences income statement Correlations
Click cells to compare fundamentals
Willow Biosciences Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Willow Biosciences income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Interest Expense | 48.1K | 40K | 27K | 26K | 142K | 149.1K | |
| Other Operating Expenses | 13.1M | 16.9M | 23.3M | 19.2M | 14.6M | 15.4M | |
| Operating Income | (46.1M) | (23.1M) | (23.3M) | (18.4M) | (13.5M) | (12.8M) | |
| Ebit | (13.0M) | (16.7M) | (22.8M) | (18.1M) | (13.5M) | (12.8M) | |
| Ebitda | (10.8M) | (13.5M) | (19.6M) | (15.5M) | (11.6M) | (11.0M) | |
| Total Operating Expenses | 13.1M | 16.9M | 23.3M | 19.2M | 12.8M | 13.4M | |
| Net Income | (44.6M) | (34.0M) | (6.2M) | (14.8M) | (13.0M) | (12.4M) | |
| Income Tax Expense | (1.6M) | 40K | 27K | 53K | (5K) | (4.8K) | |
| Selling General Administrative | 8.2M | 6.4M | 7.8M | 8.3M | 6.0M | 6.3M | |
| Depreciation And Amortization | 2.2M | 3.2M | 3.2M | 2.6M | 1.8M | 1.9M | |
| Income Before Tax | (46.1M) | (33.9M) | (6.1M) | (14.8M) | (13.0M) | (12.4M) | |
| Gross Profit | 4.6K | 10K | (11.4M) | (6.7M) | (659K) | (692.0K) | |
| Total Revenue | 4.6K | 10K | 133K | 821K | 1.2M | 1.2M | |
| Net Income Applicable To Common Shares | (44.6M) | (33.9M) | (6.1M) | (14.8M) | (13.3M) | (14.0M) | |
| Research Development | 2.7M | 7.3M | 11.5M | 7.5M | 6.8M | 6.6M |
Pair Trading with Willow Biosciences
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Willow Biosciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Willow Biosciences will appreciate offsetting losses from the drop in the long position's value.Moving together with Willow Stock
Moving against Willow Stock
The ability to find closely correlated positions to Willow Biosciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Willow Biosciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Willow Biosciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Willow Biosciences to buy it.
The correlation of Willow Biosciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Willow Biosciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Willow Biosciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Willow Biosciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Willow Stock
Willow Biosciences Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Willow Biosciences shareholders. The income statement also shows Willow investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).